C

Cannara Biotech Inc
XTSX:LOVE

Watchlist Manager
Cannara Biotech Inc
XTSX:LOVE
Watchlist
Price: 1.69 CAD -1.17% Market Closed
Market Cap: 160.4m CAD

EV/EBIT
Enterprise Value to EBIT

-22.3
Current
-13.3
Median
16.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-22.3
=
Enterprise Value
175.2m CAD
/
EBIT
-7.8m CAD
All Countries
Close
EBIT Growth EV/EBIT to Growth
CA
C
Cannara Biotech Inc
XTSX:LOVE
Average EV/EBIT: 1 878.2
Negative Multiple: -22.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.4
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.2
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.7
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
1%
10.4
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
hidden
2-Years Forward
EV/EBIT
hidden
3-Years Forward
EV/EBIT
N/A